Form 4: Serina Therapeutics CSO Exercises and Sells Stock Options Under 10b5-1 Plan

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and immediately sold the acquired common stock under a pre-arranged 10b5-1 plan.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), executed a transaction on July 29, 2025.
• The transaction was conducted under a Rule 10b5-1 pre-arranged trading plan.
• Moreadith exercised 4,196 stock options at an exercise price of $0.06 per share.
• Concurrently, he sold all 4,196 shares of common stock acquired from the exercise at a price of $6.50 per share.
• The stock options exercised were fully vested and had an expiration date of May 6, 2031.
• Following these transactions, Moreadith beneficially owns 484,490 stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (exercise and sale) under a 10b5-1 plan, which is generally not indicative of positive or negative company performance, but rather personal financial management.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary trade.
• The sale price of $6.50 per share is significantly higher than the exercise price of $0.06, indicating a substantial gain for the officer on these specific shares.

Negatives

• The Chief Scientific Officer sold all shares acquired from the option exercise, which could be interpreted as a lack of increased direct equity holding in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction (exercise and sell-to-cover or profit-taking) common across all industries, particularly in biotech/pharma where equity compensation is prevalent. It does not reflect specific industry trends beyond general compensation practices.

Comparison to Industry Standards

• Insider transactions like option exercises and sales are standard compensation mechanisms in publicly traded companies, especially in the biotechnology sector.
• The execution under a 10b5-1 plan aligns with best practices for managing insider trading compliance, similar to how executives at companies like Pfizer or Moderna might manage their equity compensation.
• The specific prices and volumes are unique to Serina Therapeutics and Randall Moreadith's compensation structure.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Scientific Officer could be viewed neutrally as a personal financial decision, or slightly negatively if interpreted as a lack of increased conviction, though the 10b5-1 plan mitigates this. The transaction itself does not directly impact company operations or financial health.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (exercise and sale of stock options) by the Chief Scientific Officer under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial planning and compensation realization, not an indication of the company's fundamental performance or future prospects. Therefore, it provides no new information that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Serina Therapeutics, SER, Randall Moreadith, Chief Scientific Officer, Stock Option Exercise, Stock Sale, Insider Trading, Form 4, 10b5-1 Plan, Equity Compensation